Full-Time

Senior Manager

Gxp Quality

Posted on 11/26/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Senior

Boston, MA, USA

Office located at 201 Brookline Avenue, Fenway area, Boston, Massachusetts.

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s Degree in a scientific discipline; advanced degree preferred
  • At least 7 years in the pharmaceutical industry with 5 years in GCP QA
  • Solid understanding of regulations and guidance for GCP, GLP, and GVP
  • Experience with US and international clinical studies
  • Excellent verbal and written communication skills
  • Experience reviewing clinical documents
  • Good organizational skills and ability to work independently
  • Collaborative problem-solver
  • Able to travel domestically and internationally approximately 25% of the time
Responsibilities
  • You will provide GCP/GLP/GVP QA oversight and support to cross functional stakeholders
  • Support development of the annual GCP/GLP/GVP audit schedule
  • Conduct and/or oversee GCP/GLP/GVP audits through closure as per the annual audit schedule, to include clinical investigator sites, CROs/vendors, process, system, study project, and document audits, to assure compliance with global regulations, guidance, and internal procedures
  • Track and effectively communicate deviation and audit trends to stakeholders
  • Identify, investigate, escalate, track, and resolve quality issues both internally and externally
  • Liaise with QA counterpart at CROs and vendors
  • Assist in preparing for, and hosting regulatory inspections with cross functional stakeholders
  • Conduct QA review of GCP protocols, ICFs, CSRs, and other clinical trial specific documents
  • Conduct QA review of GLP reports and validation plans
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

N/A

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

20%

2 year growth

87%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tango's recent $80 million private placement financing strengthens their financial position and supports ongoing R&D efforts.
  • The company's ability to secure Orphan Drug Designation and Fast Track Designation for their therapies highlights their potential to bring innovative treatments to market quickly.
  • Participation in high-profile investor conferences and scientific meetings enhances Tango's visibility and credibility in the biotech community.

What critics are saying

  • The discontinuation of the TNG348 program due to liver toxicity raises concerns about the safety and viability of their drug candidates.
  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a leading position.

What makes Tango Therapeutics unique

  • Tango Therapeutics leverages the principle of synthetic lethality to develop cancer treatments, a unique approach that specifically targets cancer cells while sparing healthy ones.
  • Their strategic collaborations with larger pharmaceutical companies like Gilead Sciences provide financial support and accelerate the development and commercialization of their therapies.
  • Tango's robust pipeline and focus on precision oncology, including targeting MTAP-deleted solid tumors and BRCA1/2 mutations, set them apart in the oncology market.

Help us improve and share your feedback! Did you find this helpful?